Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 151

1.

Effect of different genetics variants: CYP2C9*2, CYP2C9*3 of cytochrome P-450 CYP2C9 and 1639G>A of the VKORC1 gene; On acenocoumarol requirement in Moroccan patients.

Smires FZ, Habbal R, Moreau C, Assaidi A, Loriot MA, Nadifi S.

Pathol Biol (Paris). 2013 Jun;61(3):88-92. doi: 10.1016/j.patbio.2012.10.002. Epub 2012 Nov 30.

PMID:
23201087
2.

Influence of genetics and non-genetic factors on acenocoumarol maintenance dose requirement in Moroccan patients.

Smires FZ, Moreau C, Habbal R, Siguret V, Fadili S, Golmard JL, Assaidi A, Beaune P, Loriot MA, Nadifi S.

J Clin Pharm Ther. 2012 Oct;37(5):594-8. doi: 10.1111/j.1365-2710.2012.01340.x. Epub 2012 Apr 8.

PMID:
22486182
4.

VKORC1 and CYP2C9 allelic variants influence acenocoumarol dose requirements in Greek patients.

Markatos CN, Grouzi E, Politou M, Gialeraki A, Merkouri E, Panagou I, Spiliotopoulou I, Travlou A.

Pharmacogenomics. 2008 Nov;9(11):1631-8. doi: 10.2217/14622416.9.11.1631.

PMID:
19018719
5.

Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity.

Bodin L, Verstuyft C, Tregouet DA, Robert A, Dubert L, Funck-Brentano C, Jaillon P, Beaune P, Laurent-Puig P, Becquemont L, Loriot MA.

Blood. 2005 Jul 1;106(1):135-40. Epub 2005 Mar 24.

6.

The c.-1639G > A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients.

Montes R, Ruiz de Gaona E, Martínez-González MA, Alberca I, Hermida J.

Br J Haematol. 2006 Apr;133(2):183-7.

PMID:
16611310
7.

VKORC1 -1639G>A and CYP2C9*3 are the major genetic predictors of phenprocoumon dose requirement.

Puehringer H, Loreth RM, Klose G, Schreyer B, Krugluger W, Schneider B, Oberkanins C.

Eur J Clin Pharmacol. 2010 Jun;66(6):591-8. doi: 10.1007/s00228-010-0809-2. Epub 2010 Apr 8.

PMID:
20376629
8.

Genetic determinants of acenocoumarol and phenprocoumon maintenance dose requirements.

Cadamuro J, Dieplinger B, Felder T, Kedenko I, Mueller T, Haltmayer M, Patsch W, Oberkofler H.

Eur J Clin Pharmacol. 2010 Mar;66(3):253-60. doi: 10.1007/s00228-009-0768-7. Epub 2009 Dec 18.

PMID:
20020283
9.

The impact of the CYP2C9 and VKORC1 polymorphisms on acenocoumarol dose requirements in a Romanian population.

Buzoianu AD, Militaru FC, Vesa SC, Trifa AP, Crişan S.

Blood Cells Mol Dis. 2013 Mar;50(3):166-70. doi: 10.1016/j.bcmd.2012.10.010. Epub 2012 Nov 16.

PMID:
23159639
10.

Effect of CYP2C9 and VKORC1 genetic polymorphisms on mean daily maintenance dose of acenocoumarol in South Indian patients.

Krishna Kumar D, Madhan S, Balachander J, Sai Chandran BV, Thamijarassy B, Adithan C.

Thromb Res. 2013 Apr;131(4):363-7. doi: 10.1016/j.thromres.2013.02.006. Epub 2013 Mar 6.

PMID:
23473641
11.

Pharmacogenetics of oral anticoagulants: a basis for dose individualization.

Stehle S, Kirchheiner J, Lazar A, Fuhr U.

Clin Pharmacokinet. 2008;47(9):565-94. Review.

PMID:
18698879
12.

Influence of CYP2C9 and VKORC1 polymorphisms on warfarin and acenocoumarol in a sample of Lebanese people.

Esmerian MO, Mitri Z, Habbal MZ, Geryess E, Zaatari G, Alam S, Skouri HN, Mahfouz RA, Taher A, Zgheib NK.

J Clin Pharmacol. 2011 Oct;51(10):1418-28. doi: 10.1177/0091270010382910. Epub 2010 Dec 8.

PMID:
21148049
13.

Factors affecting warfarin dose requirements and quality of anticoagulation in adult Egyptian patients: role of gene polymorphism.

Bazan NS, Sabry NA, Rizk A, Mokhtar S, Badary OA.

Ir J Med Sci. 2014 Jun;183(2):161-72. doi: 10.1007/s11845-013-0978-y. Epub 2013 Jun 27.

PMID:
23800980
14.

[Effect of VKORC1 and CYP2C9 variants on dosage of oral anticoagulants in Chilean individuals].

Benavides F, Grossman N, Poggi H, Nieto E, Bertrán A, Araos D, Vásquez M, Ibarra I, Cáceres F, Espinoza K, Lagos M, Repetto M G.

Rev Med Chil. 2015 Nov;143(11):1369-76. doi: 10.4067/S0034-98872015001100001. Spanish. Erratum in: Rev Med Chil. 2016 Jan;144(1):136-7. Lagos, Marcel [corrected to Lagos, Marcela].

15.

Pharmacogenetics of acenocoumarol in patients with extreme dose requirements.

Pérez-Andreu V, Roldán V, López-Fernández MF, Antón AI, Alberca I, Corral J, Montes R, García-Barberá N, Ferrando F, Vicente V, González-Conejero R.

J Thromb Haemost. 2010 May;8(5):1012-7. doi: 10.1111/j.1538-7836.2010.03800.x. Epub 2010 Feb 9.

16.

Pharmacogenetics aspects of oral anticoagulants therapy.

Militaru FC, Vesa SC, Pop TR, Buzoianu AD.

J Med Life. 2015 Apr-Jun;8(2):171-5.

17.

Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians.

Borgiani P, Ciccacci C, Forte V, Romano S, Federici G, Novelli G.

Pharmacogenomics. 2007 Nov;8(11):1545-50.

PMID:
18034619
18.

High prevalence of VKORC1*3 (G9041A) genetic polymorphism in north Indians: A study on patients with cardiac disorders on acenocoumarol.

Sehgal T, Hira JK, Ahluwalia J, Das R, Vijayvergiya R, Rana SS, Varma N.

Drug Discov Ther. 2015 Dec;9(6):404-10. doi: 10.5582/ddt.2015.01066.

19.

Impact of genetic and clinical factors on dose requirements and quality of anticoagulation therapy in Polish patients receiving acenocoumarol: dosing calculation algorithm.

Wolkanin-Bartnik J, Pogorzelska H, Szperl M, Bartnik A, Koziarek J, Bilinska ZT.

Pharmacogenet Genomics. 2013 Nov;23(11):611-8. doi: 10.1097/FPC.0000000000000004.

PMID:
24108193
20.

A vitamin K epoxide reductase-oxidase complex gene polymorphism (-1639G>A) and interindividual variability in the dose-effect of vitamin K antagonists.

Stepien E, Branicka A, Ciesla-Dul M, Undas A.

J Appl Genet. 2009;50(4):399-403. doi: 10.1007/BF03195700.

PMID:
19875892

Supplemental Content

Support Center